Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Lin

Showing results (1-10 of 287) with videos related to

Pageof 29
Sort By:
The Urologic Clinics of North America|July 29, 2015
Testicular Cancer. PrefaceDaniel W Lin
Nature Clinical Practice. Urology|November 1, 2007
Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?Daniel W Lin
The Journal of Urology|December 27, 2022
Point-Counterpoint: Active Surveillance Should Still Be Preferred Management for All (or Nearly All) Men With Low-risk Prostate CancerDaniel W Lin
Urologic Oncology|May 6, 2009
Beyond PSA: utility of novel tumor markers in the setting of elevated PSADaniel W Lin
The Journal of Urology|October 20, 2009
Editorial commentDaniel W Lin
European Urology|April 24, 2007
Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomyDaniel W Lin
Urology|March 26, 2014
Editorial commentDaniel W Lin
European Urology|March 13, 2018
Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding RoadBruce Montgomery, Daniel W Lin
Urologic Oncology|December 11, 2012
Current status of focal primary therapy for prostate cancerJim C Hu, Daniel W Lin
Urologic Oncology|July 17, 2012
The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. IntroductionDaniel W Lin, Neal D Shore
Pageof 29

Showing results (1-10 of 287) with videos related to

Sort By:
Pageof 29
The Urologic Clinics of North America|July 29, 2015
Testicular Cancer. PrefaceDaniel W Lin
Nature Clinical Practice. Urology|November 1, 2007
Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?Daniel W Lin
The Journal of Urology|December 27, 2022
Point-Counterpoint: Active Surveillance Should Still Be Preferred Management for All (or Nearly All) Men With Low-risk Prostate CancerDaniel W Lin
Urologic Oncology|May 6, 2009
Beyond PSA: utility of novel tumor markers in the setting of elevated PSADaniel W Lin
The Journal of Urology|October 20, 2009
Editorial commentDaniel W Lin
European Urology|April 24, 2007
Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomyDaniel W Lin
Urology|March 26, 2014
Editorial commentDaniel W Lin
European Urology|March 13, 2018
Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding RoadBruce Montgomery, Daniel W Lin
Urologic Oncology|December 11, 2012
Current status of focal primary therapy for prostate cancerJim C Hu, Daniel W Lin
Urologic Oncology|July 17, 2012
The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. IntroductionDaniel W Lin, Neal D Shore
Pageof 29